High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

Conditions:   Hypercholesterolemia;   Familial Hypercholesterolemia
Intervention:   Other: No intervention
Sponsor:   Amgen
Not yet recruiting - verified June 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Recruiting - verified June 2016

A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)

Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe 10 mg;   Drug: Rosuvastatin 2.5 mg;   Drug: Placebo for Ezetimibe;   Drug: Placebo for Rosuvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2016

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Not yet recruiting - verified June 2016

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Condition:   Hypercholesterolemia
Interventions:   Biological: Evolocumab;   Drug: Ezetimibe;   Biological: Evolocumab;   Drug: Ezetimibe
Sponsors:   Amgen;   Data Monitoring Committee (DMC)
Recruiting - verified June 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2016

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2016

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Condition:   Hypercholesterolemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo (for injection training only)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2016

Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Evolocumab;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified June 2016

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Condition:   Hypercholesterolemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Enrolling by invitation - verified June 2016

Hispanic Secondary Stroke Prevention Initiative

Condition:   Stroke
Interventions:   Behavioral: Community Health Worker (CHW) home visits, coaching phone calls, group sessions .;   Other: usual care and health education brochures every 4 months.
Sponsors:   University of Miami;   National Institute on Minority Health and Health Disparities (NIMHD)
Recruiting - verified June 2016

Carnitine for the Treatment of Atherosclerosis.

Condition:   Metabolic Syndrome
Interventions:   Dietary Supplement: L-carnitine capsules;   Dietary Supplement: Cellulose capsules
Sponsors:   Queen's University;   Heart and Stroke Foundation of Canada
Recruiting - verified June 2016

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Completed - verified June 2016

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified June 2016

Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Intervention:   Drug: REGN727 (SAR236553)
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Active, not recruiting - verified June 2016

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions:   Hypercholesterolemia;   Heterozygous Familial
Interventions:   Drug: mipomersen sodium 200 mg;   Drug: Placebo;   Drug: mipomersen sodium 70 mg
Sponsor:   Genzyme, a Sanofi Company
Completed - verified June 2016

Switch to Unboosted Atazanavir With Tenofovir Study

Condition:   HIV Infection
Interventions:   Drug: atazanavir;   Drug: atazanavir/ritonavir
Sponsor:   University of British Columbia
Completed - verified June 2016

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Conditions:   Atherosclerosis;   Hypercholesterolemia
Interventions:   Drug: Statin Drugs;   Other: HMG-CoA Reductase Inhibitors
Sponsor:   National Institutes of Health Clinical Center (CC)
Active, not recruiting - verified March 2016

Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis

Conditions:   Psoriasis;   Cardiovascular Diseases;   Dyslipidemia
Intervention:  
Sponsor:   George Washington University
Completed - verified February 2016

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

Conditions:   Psoriasis;   Nonalcoholic Fatty Liver Disease
Intervention:  
Sponsor:   George Washington University
Completed - verified February 2016

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Lapaquistat acetate and stable statin therapy;   Drug: Stable statin therapy
Sponsor:   Takeda
Terminated - verified June 2016